Cord Blood Study Finds Broader PFAS Exposure Before Birth

A new analysis of archived umbilical cord blood suggests that prenatal exposure to per- and polyfluoroalkyl substances, or PFAS, is chemically broader than conventional targeted tests can show. Researchers reported 42 confirmed or tentatively identified PFAS across samples from 120 babies in the Cincinnati-based HOME Study.

The number is important, but it needs a precise reading. The researchers did not show that every infant carried all 42 substances, that the chemicals accumulated in fetal organs or that the measured exposures caused disease. They demonstrated that a method designed to search beyond a short list can reveal many more PFAS signals than a standard targeted panel.

The Samples Came From 2003 to 2006 Births

The study, published in Environmental Science & Technology, used cord-blood samples collected between 2003 and 2006. Cord blood is a record of exposure at birth, and the archived samples gave the team an opportunity to examine a birth cohort whose participants are now adolescents.

That timing also limits what the result says about exposure today. The study describes samples collected roughly two decades ago, not a current national survey of newborns. PFAS production and use have changed over that period, and a cohort from one metropolitan area cannot establish the present distribution of exposures in every population.

The research question was methodological as well as environmental. Certified analytical standards do not exist for many members of the large PFAS class. A targeted assay can quantify compounds selected in advance, but it will not capture a chemical that is absent from its list. The team therefore combined targeted measurement with PFAS-focused nontargeted analysis.

Forty-Two Signals Do Not Mean Forty-Two Diagnoses

The nontargeted analysis putatively identified 42 PFAS in cord blood, including perfluorinated compounds, polyfluorinated compounds and fluorotelomers. Four were also detected in the targeted analysis. “Putatively identified” is a crucial qualification: without a matching certified standard for every substance, a chemical signal may be assigned with varying levels of confidence rather than confirmed and quantified in the same way as a targeted result.

The researchers then built two summary measures. One represented concentrations from targeted analysis, while a PFAS-omics score summarized relative abundance from the broader nontargeted screen. The aim was to estimate total exposure burden without pretending that every detected compound could be measured on one conventional concentration scale.

Earlier work using limited panels had often found lower PFAS burdens among babies born to mothers who had previously given birth. This study found that pattern in its targeted exposure score, but not in the broader PFAS-omics score. The difference suggests that conclusions about exposure patterns can depend on which chemicals a method is capable of seeing.

The Study Did Not Test Health Effects

The paper was an exploratory exposure analysis. It did not report birth defects, immune damage, cancer, developmental delay or another clinical outcome caused by the 42 identified substances. Mount Sinai's research summary explicitly says that many of the detected PFAS are not commonly included in traditional testing and that their health effects are unknown.

Previous research has associated prenatal exposure to some PFAS with outcomes including lower birth weight, preterm birth and altered immune responses. Those findings provide a reason to investigate exposure, but they cannot be transferred automatically to every chemical signal in this study. PFAS differ in structure, persistence and biological behavior, while observational associations do not establish the effect of an individual compound or mixture in a particular child.

The authors plan to examine whether the cumulative exposure scores relate to later health data from the same cohort. That next step may test whether the broader measurement captures risks that smaller panels miss. Until then, the scores are exposure tools, not diagnostic tests and not predictions for an individual baby.

Better Measurement Creates a Regulatory Question

PFAS are used in products including nonstick materials, stain-resistant fabrics, food packaging and firefighting foams. Their persistence has made exposure a long-term environmental problem. Yet this study did not identify each participant's exposure source, compare consumer products or evaluate a specific regulation.

Its policy significance is more fundamental. A monitoring system built around a handful of well-known compounds may describe only the portion of a chemical class for which standards and assays already exist. Broader methods can expose that blind spot, but regulators still need validated identities, concentrations, toxicology and population data before assigning risk to each finding.

Routine cord-blood PFAS screening is not a clinical recommendation from this paper. The immediate obligation belongs upstream: researchers and regulators must determine which compounds are present, which exposures can be reduced and which measurements predict harm. Finding a wider chemical footprint is not proof of injury, but leaving most of that footprint unmeasured is not a defensible safety strategy either.